Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN) to report ($0.02) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Alpine Immune Sciences’ earnings. The lowest EPS estimate is ($0.52) and the highest is $1.51. Alpine Immune Sciences posted earnings of ($0.28) per share in the same quarter last year, which would indicate a positive year over year growth rate of 92.9%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 11th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full-year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.96) to $0.21. For the next year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.28) to $0.73. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, August 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.17). Alpine Immune Sciences had a negative net margin of 190.22% and a negative return on equity of 60.24%. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $6.59 million.
In related news, CEO Mitchell Gold sold 3,484 shares of Alpine Immune Sciences stock in a transaction dated Wednesday, September 15th. The stock was sold at an average price of $10.00, for a total value of $34,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 16,436 shares of company stock valued at $164,455. Corporate insiders own 57.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Alpine Immune Sciences by 1,933.8% during the 2nd quarter. BlackRock Inc. now owns 544,155 shares of the biotechnology company’s stock worth $4,898,000 after acquiring an additional 517,399 shares in the last quarter. Ikarian Capital LLC grew its stake in Alpine Immune Sciences by 6,330.4% during the 1st quarter. Ikarian Capital LLC now owns 304,739 shares of the biotechnology company’s stock worth $3,230,000 after buying an additional 300,000 shares during the last quarter. State Street Corp purchased a new position in Alpine Immune Sciences during the 2nd quarter worth approximately $1,558,000. Opaleye Management Inc. purchased a new position in shares of Alpine Immune Sciences in the 1st quarter valued at approximately $1,659,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Alpine Immune Sciences in the 2nd quarter valued at approximately $1,382,000. 55.07% of the stock is owned by hedge funds and other institutional investors.
Shares of Alpine Immune Sciences stock opened at $10.00 on Friday. The company has a market cap of $239.15 million, a PE ratio of -6.85 and a beta of 1.65. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average of $9.03 and a 200-day moving average of $10.36. Alpine Immune Sciences has a 1-year low of $7.21 and a 1-year high of $16.37.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies.
Featured Story: What is the Beige Book?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.